Ex-Cedilla CEO Glucksmann explores ‘new frontier’ at Sensorium; R&D chief out at Merck women’s health spinoff Organon

Alexandra Glucksmann is always looking for “the next frontier” in medicine. After spending most of her career in genetic diseases, rare diseases and oncology, her next pursuit is in mental health.

The longtime biopharma executive is the next CEO at Sensorium Therapeutics, a biotech leveraging machine learning to develop new mental health treatments, starting from plant components that are known to be psychoactive. The company’s lead program in anxiety is currently in preclinical testing.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。